Article Publish Status: FREE
Abstract Title:

Effect of Combined Treatment With Folic Acid, Vitamin B, and Vitamin Bon Plasma Biomarkers of Inflammation and Endothelial Dysfunction in Women.

Abstract Source:

J Am Heart Assoc. 2018 May 18 ;7(11). Epub 2018 May 18. PMID: 29776960

Abstract Author(s):

William G Christen, Nancy R Cook, Martin Van Denburgh, Elaine Zaharris, Christine M Albert, JoAnn E Manson

Article Affiliation:

William G Christen


BACKGROUND: The aim of this study was to determine whether reducing plasma homocysteine concentrations with long-term, combined treatment with folic acid, vitamin B, and vitamin Balters plasma biomarkers of inflammation and endothelial dysfunction in women at increased risk of cardiovascular disease.

METHODS AND RESULTS: We conducted a blood substudy of 300 treatment-adherent participants (150 in the active treatment group, 150 in the placebo group) in the WAFACS (Women's Antioxidant and Folic Acid Cardiovascular Study), a randomized, double-blind, placebo-controlled trial testing a daily combination of folic acid (2.5 mg), vitamin B(50 mg), vitamin B(1 mg), or matching placebo, in cardiovascular disease prevention among women at increased risk of cardiovascular disease. Plasma concentration of 3 biomarkers of inflammation (C-reactive protein, interleukin-6, and fibrinogen) and a biomarker of endothelial dysfunction (intercellular adhesion molecule 1) were measured at baseline and at the end of treatment and follow-up. After 7.3 years of combined treatment with folic acid, vitamin B, and vitamin B, homocysteine concentrations were reduced by 18% in the active treatment group as compared with the placebo group (<0.001). However, there was no difference between treatment groups in change in blood concentration from baseline to follow-up for C-reactive protein (=0.77), interleukin-6 (=0.91), intercellular adhesion molecule 1 (=0.38), or fibrinogen (=0.68).

CONCLUSIONS: These findings indicate that long-term, combined treatment with folic acid, vitamin B, and vitamin Blowers homocysteine concentrations, but does not alter major biomarkers of vascular inflammation, consistent with the lack of clinical cardiovascular disease benefit in the trial.

CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00000541.

Print Options

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2022 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.